Superworth

First Tracks Biotherapeutics TRAX

Drug Manufacturers - General, Healthcare
$45.05
−0.07%
Market cap
$1.6B
PE
n/m
one or more of the four quarters through 2026-06-30 missing
Forward PE
n/m
not a meaningful number
Price to sales
n/m
not a meaningful number
EV/EBIT
n/m
not a meaningful number
Revenue, 12 months
n/m
not a meaningful number
Net margin
n/m
not a meaningful number
Free cash flow yield
n/m
not a meaningful number

Charts

Financials

Income statement for TRAX, by quarter
Income statementQ1 FY25Q2 FY25Q1 FY26Q2 FY26
R&D$41.5M$39.3M$34M$25.6M
SG&A$9.8M$6.6M$18.9M$9.3M
−$51.3M−$45.9M−$52.8M−$34.9M
Net income−$47.2M−$42.4M−$50.5M−$33.4M
−$1.54−$1.47n/a−$0.95
30.6M28.8Mn/a35M

EPS, diluted: Q1 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY25: share-days: the 6-month average less the second quarter's.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest First Tracks Biotherapeutics' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
TRAXFirst Tracks Biotherapeutics$1.6Bn/mn/an/mn/mn/m
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
PCRXPacira BioSciences$1.5B104×65.7×1.9×+6%2.0%
ANABAnaptysbio$1.4B10.3×99.3×n/mn/mn/m
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
AMPHAmphastar Pharmaceuticals$1.1B15.9×20.5×1.6×+1%10.8%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
Peer median$1.5B13.1×17.9×2.0×+11%13.3%

More on First Tracks Biotherapeutics

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .